CTLA4 and hepatocellular carcinoma: Ongoing studies are evaluating whether the quantitative or spatial analysis of PD-L1 and CTLA-4 by IHC could identify subgroups of HCC patients who are more likely to benefit from immunotherapy or to experience immune-related adverse events.